Research Progress of Salinomycin and CD47 in the Treatment of Glioma

神经胶质瘤是最常见的脑肿瘤，占恶性脑肿瘤的80%，尽管近来一直在不懈地探索神经胶质瘤的新治疗方法，但在改善患者生存结果方面进展有限。许多障碍阻碍了神经胶质瘤的有效治疗，包括免疫抑制性肿瘤微环境、血脑屏障和广泛的异质性。尽管存在这些挑战，但免疫疗法正在成为一种有前途的途径，可能为神经胶质瘤的治疗提供新的希望。巨噬细胞在肿瘤免疫治疗中发挥重要作用，CD47与巨噬细胞上的SIRP胞外结构域结合，从而抑制巨噬细胞的吞噬作用。近来研究发现，盐霉素在包括神经胶质瘤的各类肿瘤中具有抗肿瘤的效应。本文以此为目的，对盐霉素与CD47在神经胶质瘤治疗中的研究进行综述，旨在为盐霉素与CD47在神经胶质瘤的临床治疗过程中的应用和推广提供依据。Glioma is the most common brain tumor, accounting for 80% of malignant brain tumors. Despite continuous exploration of new treatment methods for glioma, progress in improving patient survival outcomes has been limited. Many obstacles hinder effective treatment of glioblastoma, including immunosuppressive tumor microenvironment, blood-brain barrier, and widespread heterogeneity. Despite these challenges, immunotherapy is becoming a promising approach that may provide new hope for the treatment of glioblastoma. Macrophages play an important role in tumor immunotherapy, as CD47 binds to the extracellular domain of SIRP on macrophages, thereby inhibiting their phagocytic activity. Recent studies have found that salinomycin has anti-tumor effects in various types of tumors, including glioma. This article aims to review the research on the treatment of glioblastoma with streptomycin and CD47, providing a basis for the clinical application and promotion of streptomycin and CD47 in the treatment of glioblastoma.